Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0000950170-25-013753

Options or other derivatives

  • Chief Development Officer acquired 110,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Yeleswaram Krishnaswamy Chief Development Officer 2025-02-03 Grant or award · Stock Option (Right to Buy) +110,000 110,000 D
Loading xslF345X05/ownership.xml…